Further combined survival analysis also confirmed that AML patients with high Wnt10A and low Wnt11 expression have the longest EFS and OS in the chemotherapy group, suggesting that the combination of Wnt10A and Wnt11 may be a novel prognostic marker for AML and superior to single Wnt gene. This evidence concerns the gene WNT11 and acute myeloid leukemia.